Analysis Group Ltd
Industry / private company
Location:
London,
United Kingdom (GB)
Association between event-free survival and overall survival in early-stage triple-negative breast cancer (2024)
Huang M, Fasching P, Haiderali A, Xue W, Pan W, Karantza V, Yang F, et al.
Journal article, Review article
Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy (2022)
Fasching P, Huang M, Haiderali A, Xue W, Pan W, Karantza V, Yang F, et al.
Conference contribution
Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States (2022)
Fasching P, Huang M, Haiderali A, Xue W, Pan W, Zhou ZY, Hu P, et al.
Conference contribution